About Varmx
Varmx is a company based in Leiden (Netherlands) founded in 2015 by Pieter H Reitsma.. Varmx has raised $77.19 million across 8 funding rounds from investors including EQT, European Commission and Rijksdienst voor Ondernemend Nederland. Varmx offers products and services including VMX-C001. Varmx operates in a competitive market with competitors including Hemab, AbFero Pharmaceuticals, Alveron Pharma, TargED and Pangen Biotech, among others.
- Headquarter Leiden, Netherlands
- Founders Pieter H Reitsma
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Varmx B.V.
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$77.19 M (USD)
in 8 rounds
-
Latest Funding Round
$32.3 M (USD), Series B
May 25, 2023
-
Investors
EQT
& 13 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Varmx
Varmx offers a comprehensive portfolio of products and services, including VMX-C001. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Restores coagulation to manage bleeding in FXa-DOAC patients effectively.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Varmx
Varmx has successfully raised a total of $77.19M across 8 strategic funding rounds. The most recent funding activity was a Series B round of $32.3 million completed in May 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series B — $32.3M
- First Round First Round
- Investors Count 14
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2023 | Amount | Series B - Varmx | Valuation | Sound Bioventures , European Commission | |
| Sep, 2022 | Amount | Grant - Varmx | Valuation |
investors |
|
| Oct, 2021 | Amount | Grant - Varmx | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Varmx
Varmx has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include EQT, European Commission and Rijksdienst voor Ondernemend Nederland. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Founded Year | Domain | Location | |
|
EQT is recognized as a global investment organization focused on value creation.
|
Founded Year | Domain | Location | |
|
Early & late stage VC firm investing primarily in Netherlands
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Varmx
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Varmx
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Varmx Comparisons
Competitors of Varmx
Varmx operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Hemab, AbFero Pharmaceuticals, Alveron Pharma, TargED and Pangen Biotech, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Preventative therapies for rare bleeding and thrombotic disorders are developed.
|
|
| domain | founded_year | HQ Location |
Oral iron chelators are developed for iron overload disease treatment.
|
|
| domain | founded_year | HQ Location |
Drugs for haemorrhagic stroke and intracranial haemorrhage are developed.
|
|
| domain | founded_year | HQ Location |
Biological drugs for thrombosis treatment are developed by the company.
|
|
| domain | founded_year | HQ Location |
Developer of biosimilars and biologics
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Varmx
Frequently Asked Questions about Varmx
When was Varmx founded?
Varmx was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Where is Varmx located?
Varmx is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Is Varmx a funded company?
Varmx is a funded company, having raised a total of $77.19M across 8 funding rounds to date.
What does Varmx do?
VarmX, a spin-out company from the Leiden University Medical Center, is focussed on development and manufacturing of therapeutic proteins to restore blood clotting in bleeding patients. Its lead product PseudoXa is a modified recombinant human coagulation factor X and is being developed to restore blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban. DOACS are taken by patients for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs.
Who are the top competitors of Varmx?
Varmx's top competitors include Hemab, Cadrenal Therapeutics and Alveron Pharma.
What products or services does Varmx offer?
Varmx offers VMX-C001.
Who are Varmx's investors?
Varmx has 14 investors. Key investors include EQT, European Commission, Rijksdienst voor Ondernemend Nederland, European Union, and Life Sciences Partners.